NovoCure (BSP:N2VC34) Beginning Cash Position: R$499 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:N2VC34 NovoCure Ltd BSP:N2VC34
48 GF Score
Price R$7.98
GF Value R$8.49
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is NovoCure Beginning Cash Position?

NovoCure BSP:N2VC34 48 Beginning Cash Position is R$499 Mil as of Jun. 2026. GuruFocus rates BSP:N2VC34 with a GF Score™ of 48/100 and a GF Value™ of R$8.49 (Fairly Valued). The stock has 5 warning signs investors should review.

NovoCure's Beginning Cash Position for the quarter that ended in Jun. 2026 was R$499 Mil.

NovoCure's quarterly Beginning Cash Position declined from Dec. 2025 (R$1,880 Mil) to Mar. 2026 (R$541 Mil) and declined from Mar. 2026 (R$541 Mil) to Jun. 2026 (R$499 Mil).

NovoCure's annual Beginning Cash Position increased from Dec. 2023 (R$568 Mil) to Dec. 2024 (R$1,480 Mil) but then declined from Dec. 2024 (R$1,480 Mil) to Dec. 2025 (R$906 Mil).

NovoCure Beginning Cash Position Related Terms

NovoCure Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for NovoCure's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NovoCure Beginning Cash Position Chart

NovoCure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,392.08 1,099.48 567.56 1,479.88 906.16

NovoCure Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 717.80 815.89 1,880.24 540.69 498.70
BSP:N2VC34
48GF Score
NovoCure Ltd BSP:N2VC34
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NovoCure Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of R$499 Mil mean?
NovoCure (BSP:N2VC34) has a Beginning Cash Position of R$499 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on NovoCure and its competitors.
Is NovoCure's Beginning Cash Position too high?
NovoCure's current Beginning Cash Position is R$499 Mil. Overall, NovoCure has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's Beginning Cash Position compare to NEOG and AXGN?
NovoCure's Beginning Cash Position of R$499 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Medical Devices & Instruments company?
A good Beginning Cash Position depends on the Medical Devices & Instruments industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on NovoCure and its competitors. NovoCure's current Beginning Cash Position is R$499 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Fairly Valued. The stock's GF Value™ is R$8.49, compared to a current price of R$7.98 — trading 6% below its estimated fair value. The current Beginning Cash Position is R$499 Mil. NovoCure's overall GF Score™ is 48/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current Beginning Cash Position is R$499 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NovoCure (BSP:N2VC34) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of R$7.98 is trading 6% below its estimated GF Value™ of R$8.49. GuruFocus considers NovoCure to be Fairly Valued.

Key valuation signals for BSP:N2VC34:

  • Beginning Cash Position: R$499 Mil
  • GF Value™: R$8.49 vs. price of R$7.98 (6% below fair value)
  • GF Score™: 48/100 with 5 warning signs

No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
48GF Score

Get the complete analysis for BSP:N2VC34

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$7.98
Price
R$8.49
GF Value